読み込み中
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves’ disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women’s health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.
前日終値
$38.37
+$1.47 · +3.98%
日中の時刻はETです。市場データは遅延する場合があります。
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves’ disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women’s health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.
日中レンジ
現在 $38.37
52週レンジ
現在 $38.37
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
2
著しい割高
センチメント
61
強気
リスク
55
やや高いリスク
モメンタム
69
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves’ disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women’s health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.
日中レンジ
現在 $38.37
52週レンジ
現在 $38.37
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 |
|---|---|---|---|
| 売上高 | 4595.1万 USD | 107.5万 USD | 15.1万 USD |
| 粗利益 | 4595.1万 USD | 107.5万 USD | 15.1万 USD |
| 研究開発 | 9758.4万 USD | 6533.7万 USD | 3597.9万 USD |
| 販売・一般管理 | 2916.4万 USD | 1656.1万 USD | 972.2万 USD |
| 営業費用 | 1.27億 USD | 8189.8万 USD | −192.4万 USD |
| 受取利息 | 1953万 USD | 861.7万 USD | 278.6万 USD |
| 減価償却費と償却費 | 160.4万 USD | 140.1万 USD | 84.8万 USD |
| 営業利益 | −8079.7万 USD | −8082.3万 USD | 207.5万 USD |
| 純利益 | −4887.9万 USD | −7179.8万 USD | 418万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$50.40
上昇余地（31.35%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI3539.04万0.00%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM2155.64万0.03%787.4億 USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF1016.98万0.01%954億 USD0.05%$235+0.80%
State Street SPDR S&P Pharmaceuticals ETFXPH852.46万1.85%4.62億 USD0.35%$64.65+1.60%
First Trust Small Cap Growth AlphaDEX FundFYC838.67万0.62%13.49億 USD0.70%$115.36+1.35%
iShares Biotechnology ETFIBB834.48万0.08%108.2億 USD0.44%$206.49+3.00%
iShares Russell 2000 Growth ETFIWO496.86万0.04%139.17億 USD0.24%$356.78+0.94%
Vanguard Russell 2000 ETFVTWO485.18万0.03%180億 USD0.06%$112.66+0.50%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFState Street SPDR S&P Pharmaceuticals ETFXPHFirst Trust Small Cap Growth AlphaDEX FundFYCiShares Biotechnology ETFIBBiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
